Biopharmaceutical Third-Party Logistics Market Report 2026

The biopharmaceutical third-party logistics market size has grown strongly in recent years. It will grow from $150.5 billion in 2025 to $161.71 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in biologics and vaccine production, rising outsourcing of logistics services by pharmaceutical companies, expansion of global biopharmaceutical supply chains, increasing regulatory requirements for drug transportation, limited in-house logistics capabilities among biopharma firms.

The biopharmaceutical third-party logistics market size is expected to see strong growth in the next few years. It will grow to $221.15 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized medicines, expansion of cell and gene therapy distribution, rising investments in smart logistics platforms, growing focus on end-to-end supply chain visibility, increasing cross-border biopharmaceutical trade. Major trends in the forecast period include increasing adoption of advanced cold chain logistics solutions, rising demand for temperature-monitored transportation services, growing use of real-time shipment tracking platforms, expansion of specialized biopharma warehousing infrastructure, enhanced focus on regulatory-compliant logistics operations.

The increasing trend of outsourcing logistics is anticipated to drive the expansion of the biopharmaceutical third-party logistics market. Outsourcing logistics entails hiring a third party to manage all or part of a company’s logistical operations. In biopharmaceutical third-party logistics, this approach is applied to delegate cryogenic supply chain management to specialized logistics partners. For example, in February 2024, the Bureau of Transportation Statistics, a US-based division of the Department of Transportation (DOT), reported that for-hire freight shipments increased by 1.8% in December 2023 compared to December 2022, while the Freight Transportation Services Index rose from 136.6 in December 2022 to 139.1 in December 2023. Consequently, the growing trend of outsourcing logistics is expected to fuel the growth of the biopharmaceutical third-party logistics market.

Major companies in the biopharmaceutical third-party logistics market are concentrating on innovative strategies such as expanding their presence in life sciences and healthcare logistics to improve the transportation and storage of pharmaceutical and healthcare products, ensuring efficient distribution. Expansion in life sciences and healthcare logistics involves the strategic growth of logistics providers to strengthen their ability to manage and transport medical products, which is essential for timely delivery and preserving the quality of temperature-sensitive items critical for patient care. For example, in May 2025, DHL Group, a Germany-based logistics provider, inaugurated its upgraded Life Sciences & Healthcare (LSH) campus in Florstadt, Germany. The facility features ultra-cold storage areas (down to -70°C), real-time tracking systems, and GDP-certified infrastructure, allowing secure handling of temperature-sensitive biopharmaceuticals, including mRNA vaccines, clinical trial materials, and advanced therapies.

In March 2025, DHL Group, a Germany-based logistics and supply chain provider, acquired CryoPDP from Cryoport for an undisclosed amount. Through this acquisition, DHL aims to enhance its temperature-sensitive logistics capabilities, particularly for the life sciences and healthcare sector, and improve its capacity to serve clients in clinical development and advanced therapy supply chains. CryoPDP is a France-based company providing white-glove, cold-chain courier services specialized in biopharma, with extensive expertise in managing GDP-compliant transportation of temperature-sensitive and complex pharmaceutical products.

Major companies operating in the biopharmaceutical third-party logistics market are McKesson Corporation, AmerisourceBergen Corporation, United Parcel Service of America Inc., FedEx Corporation, DHL International GmbH, Kuehne + Nagel International AG, SF Express Co Ltd., DB Schenker, CH Robinson Worldwide Inc., Nippon Express Group, Expeditors International of Washington Inc., Sinotrans Limited, XPO Logistics Inc., Kerry Logistics Network Limited, Bollore Logistics, VersaCold Logistics Services, Cryoport Inc., Agility Logistics Corp, Fisher Clinical Services, CEVA Logistics Inc., LifeScience Logistics, Cold Chain Technologies LLC, Langham Logistics, Airpharm Logistics, Express Courier International, Bio Pharma Logistics.

North America was the largest region in the biopharmaceutical third party logistics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical third-party logistics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceutical third-party logistics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biopharmaceutical third-party logistics market by increasing costs associated with imported refrigerated containers, temperature-monitoring devices, specialized packaging materials, and logistics equipment used in cold chain operations. Pharmaceutical supply chains in North America and Europe are most affected due to dependence on imported logistics hardware, while Asia-Pacific faces cost pressure on export-oriented biopharma distribution. These tariffs are increasing operational costs for logistics providers and contract partners. However, they are also encouraging regional cold chain infrastructure development, local equipment sourcing, and long-term investments in domestic biopharmaceutical logistics capabilities.

The biopharmaceutical third-party logistics market research report is one of a series of new reports that provides biopharmaceutical third-party logistics market statistics, including biopharmaceutical third-party logistics industry global market size, regional shares, competitors with a biopharmaceutical third-party logistics market share, detailed biopharmaceutical third-party logistics market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical third-party logistics industry. This biopharmaceutical third-party logistics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biopharmaceutical third-party logistics involves a partner or service that provides logistics support through external entities to pharmaceutical companies. These companies outsource their transportation requirements to third-party providers to reduce costs, with the lack of in-house capabilities being a key factor driving the growth of transportation outsourcing.

The primary types of biopharmaceutical third-party logistics supply chains are cold chain and non-cold chain. The cold chain refers to a supply chain that ensures temperature control is maintained throughout the transportation of temperature-sensitive products. The range of services includes transportation, warehousing and storage, and other services utilized by pharmaceutical and biopharmaceutical companies, medical device companies, hospitals and clinics, and additional organizations.

The biopharmaceutical third-party logistics market consists of revenues earned by entities by providing biopharmaceutical third-party logistics such as domestic transportation management, international transportation management, and value-added warehousing and distribution. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.